Melissa K. Accordino

Oncology

161 Fort Washington Ave
New York, NY 10032

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 94 publications

COVID-19 in Patients With Gynecologic Cancer: A Report From the COVID-19 and Cancer Consortium.

COVID-19 in Patients With Gynecologic Cancer: A Report From the COVID-19 and Cancer Consortium.

Journal: JCO oncology advances

Published: September 01, 2026

A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab, and pertuzumab in hormone receptor (HR)-positive, HER2-positive metastatic breast cancer (ASPIRE).

A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab, and pertuzumab in hormone receptor (HR)-positive, HER2-positive metastatic breast cancer (ASPIRE).

Journal: Journal of the National Cancer Institute

Published: March 24, 2026

Thrombosis Across Female-Specific Malignancies: From Chemotherapy-Driven Risk to Prophylaxis and Drug Interactions.

Thrombosis Across Female-Specific Malignancies: From Chemotherapy-Driven Risk to Prophylaxis and Drug Interactions.

Journal: Pharmacotherapy

Published: October 31, 2025

Where Have We Been and Where Are We Going? The State of the Hematology and Medical Oncologist Workforce in America.

Where Have We Been and Where Are We Going? The State of the Hematology and Medical Oncologist Workforce in America.

Journal: JCO oncology practice

Published: October 07, 2025

ASCO State of Cancer Care in America Special Report 2025: Access to Cancer Clinical Trials in the United States.

ASCO State of Cancer Care in America Special Report 2025: Access to Cancer Clinical Trials in the United States.

Journal: JCO oncology practice

Published: October 06, 2025

Disparities in delays and outcomes in patients with HER2-positive breast cancer.

Disparities in delays and outcomes in patients with HER2-positive breast cancer.

Journal: Breast cancer research and treatment

Published: July 22, 2025

PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 20, 2025

Utilization of weight management treatment and subsequent cardiovascular events among patients with breast cancer.

Utilization of weight management treatment and subsequent cardiovascular events among patients with breast cancer.

Journal: Breast cancer research and treatment

Published: March 21, 2025

Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study.

Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 19, 2025

Continuous glucose monitoring to characterize hyperglycemia during chemotherapy for early stage breast cancer.

Continuous glucose monitoring to characterize hyperglycemia during chemotherapy for early stage breast cancer.

Journal: Breast cancer research and treatment

Published: February 10, 2025

Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).

Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).

Journal: ESMO open

Published: December 18, 2024

Association between hyperglycemia and the development of chemotherapy induced peripheral neuropathy among patients with breast cancer in the control trial.

Association between hyperglycemia and the development of chemotherapy induced peripheral neuropathy among patients with breast cancer in the control trial.

Journal: Breast cancer research : BCR

Published: September 30, 2024

Showing 1-12 of 94

Last Updated: 09/26/2026